| Identification | Back Directory | [Name]
MHY1485 | [CAS]
326914-06-1 | [Synonyms]
MHY1485
MHY-1485;MHY 1485
MHY1485 USP/EP/BP
4,6-dimorpholino-N-(4-nitrophenyl)-1,3,5-triazin-2-amine
4,6-Di-4-morpholinyl-N-(4-nitrophenyl)-1,3,5-triazin-2-amine
1,3,5-Triazin-2-amine, 4,6-di-4-morpholinyl-N-(4-nitrophenyl)-
4,6-Bis(morpholin-4-yl)-N-(4-nitrophenyl)-1,3,5-triazin-2-amine | [Molecular Formula]
C17H21N7O4 | [MDL Number]
MFCD00489974 | [MOL File]
326914-06-1.mol | [Molecular Weight]
387.393 |
| Chemical Properties | Back Directory | [Melting point ]
256-259 °C | [Boiling point ]
643.3±65.0 °C(Predicted) | [density ]
1.415±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: soluble2mg/mL, clear (warmed) | [form ]
powder | [pka]
6.19±0.10(Predicted) | [color ]
white to beige | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or DMF may be stored at -20°C for up to 3 months. | [InChI]
InChI=1S/C17H21N7O4/c25-24(26)14-3-1-13(2-4-14)18-15-19-16(22-5-9-27-10-6-22)21-17(20-15)23-7-11-28-12-8-23/h1-4H,5-12H2,(H,18,19,20,21) | [InChIKey]
MSSXBKQZZINCRI-UHFFFAOYSA-N | [SMILES]
N1=C(N2CCOCC2)N=C(N2CCOCC2)N=C1NC1=CC=C([N+]([O-])=O)C=C1 |
| Hazard Information | Back Directory | [Description]
MHY1485 is a cell-permeable activator of mTOR that has been shown to increase levels of cellular mTOR Ser2448 and downstream substrate 4E-BP Thr37/46 phosphorylation in rat liver Ac2F cells.1 It can induce cellular LC3-II accumulation in Ac2F cells and has been shown to inhibit autophagy by suppressing the fusion between autophagosomes and lysosomes.1 | [Uses]
MHY1485 has been used:
- to study the effect of mammalian target of rapamycin mTOR signalling on in vitro O-GlcNAcylation
- to inhibit autophagy
- as a mTOR agonist to demonstrate that the O-linked N-acetylglucosamine transferase- RNA helicase p68 (OGT-DDX5) axis regulates colorectal cancer cell proliferation and metastasis
| [Biochem/physiol Actions]
MHY1485 is mTOR activator that potently inhibits autophagy by suppression of fusion between autophagosomes and lysosomes. | [in vivo]
MHY1485 (intraperitoneal injection; 10?mg/kg, 2 days) blocks the autophagy signaling induced by follicle-stimulating hormone (FSH). It increases p-mTOR and p-S6K1 expression levels, whereas LC3 expression shows no marked change compared to that in the control group[3]. | Animal Model: | 4-week-old female ICR mice[3] | | Dosage: | 10?mg/kg, 2 days | | Administration: | Intraperitoneal injection | | Result: | Suppressed the autophagy level following FSH treatment.? |
| [IC 50]
mTORC1; mTORC2; Autophagy | [References]
1) Choy et al. (2012), Inhibitory effect of mTOR activator MHY1485 on autophagy: suppression of lysosomal fusion; PLoS One, 7(8) e43418
2) Cheng et al. (2015), Promotion of ovarian follicle growth following mTOR activation: synergistic effects of AKT stimulators; PLoS One, 10(2) e0117769
3) Zhao et al. (2016), MHY1485 activates mTOR and protects osteoblasts from dexamethasone; Biochem. Biophys. Res. Commun., 481 212
4) Yang et al. (2017), MHY1485 ameliorates UV-induced skin cell damages via activating mTOR-Nrf2 signaling; Oncotarget, 8 12775
5) Li and Siragy (2015), (Pro)renin receptor regulates autophagy and apoptosis in podocytes exposed to high glucose; J. Physiol. Endocrinol. Metab., 309 E302 |
|
|